CBD News Roundup: The CBD Insider 2021 US CBD Consumer Report Is Now Live

The CBD Insider 2021 US CBD Consumer Report

Here’s the latest CBD news:

  • The CBD Insider 2021 US CBD Consumer Report has just been published.
  • A new study finds CBD can offer benefits similar to anti-inflammatory drugs for menstrual cramps. 
  • A California cannabis company will pay at least $300 thousand in a settlement over CBD health claims. 
  • Trusted brand Lazarus Naturals has developed their first edible, CBD fruit tarts. 

Table of Contents

  1. The CBD Insider 2021 US CBD Consumer Report Is Now Live
  2. CBD Rivals Anti-Inflammatory Drug Effectiveness for Menstrual Pain
  3. Cannacraft Fined $300k for CBD Health Claims
  4. Lazarus Naturals Ventures Into Edibles with CBD Fruit Tarts

The CBD Insider 2021 US CBD Consumer Report Is Now Live

This Thursday (May 12), we published our annual CBD Consumer Report, for which we survey thousands of respondents on their awareness, use, and perceptions of CBD, as well as how often they have been exposed to CBD products.

We significantly upped the sample size this year, increasing from just over 1,000 to 3,519 demographically representative respondents, to more confidently call out trends in the data.

Speaking of, we asked prospective, current, and former CBD users as well as uninterested respondents about the following concepts, which make up sections of the report:

  • CBD Awareness and Exposure
  • Brand Awareness
  • Sentiment Toward CBD
  • Statements About CBD

In part two of the report, we asked each consumer segment specific questions to identify relevant findings, such as why potential consumers are hesitant to use CBD, how much CBD current consumers take, and why past consumers stopped taking it.

We were also able to identify several trends as associated with demographic information—for example, how respondent age affected their willingness to pay a certain amount for a month’s supply of CBD—and have provided all the insights from these “crosstabs” in section three of the report.

As a focal point in our mission to spread knowledge and awareness of CBD from the consumer level up, the report is free for all to access. 

CBD Rivals Anti-Inflammatory Drug Effectiveness for Menstrual Pain

The results of a clinical trial presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific meeting, which was held virtually from 4/30-5/2, have implicated CBD as potentially effective for menstrual pain.

Fertility specialist Allen Morgan, MD developed the botanically enhanced CBD product used in the study, dubbed Flow Formula, originally to help his daughter after prolonged anti-inflammatory use for menstrual cramps began to affect her stomach.

In addition to CBD, the formulation contained valerian root, ginger, turmeric, and several other botanicals.

Per the study, participants who were administered the CBD formula reported a closely comparable level of pain relief (compared to the group who received common anti-inflammatories), and throughout the trial, CBD was more effective at reducing nausea.

Absent FDA regulation, CBD sellers are still prohibited from making health claims surrounding the cannabinoid, but should a regulatory pathway soon be paved, replacement of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen will likely be at the top of the to-do list. 

Cannacraft Fined $300k for CBD Health Claims

Yet another CBD health claim case, this time a civil suit brought against California-based Cannacraft, Inc. by a California consumer protection group, was settled on May 5th for $300,000.

According to the Sonoma County District Attorney’s Office, Cannacraft was accused of making “Representations regarding the efficacy of its Care By Design products on its internet website, www.cbd.org, that were not supported by competent and reliable scientific evidence, including that, ‘cannabidiol can change gene expression and remove beta amyloid plaque, the hallmark of Alzheimer’s, from brain cells.’” 

While cannabidiol has been implicated as a potential treatment for some disorders, the key word is “potential.” These arguments have not been convincingly substantiated, which is why federal and state governments are cracking down on these very “forward” claims.

As it stands, cannabis brands are expressly forbidden from making any specific claims regarding CBD’s potential to treat pain, inflammation, or any disease or disorder whatsoever.

Also included in the stipulated judgment handed to Cannacraft at the conclusion of the proceedings were a number of provisions related to restructuring the language used in their advertisements.

Lazarus Naturals Ventures Into Edibles with CBD Fruit Tarts

One of our most trusted brands, Lazarus Naturals, has just broken into the CBD edibles market with a unique product offering: CBD fruit tarts.

Available in raspberry lime, orange pineapple, or strawberry lemon, each piece contains 25mg of CBD, totaling 1,500mg for their 60-count tubs.

Like the rest of their products, these CBD-infused fruit tarts are third-party lab tested for cannabinoids, residual solvents, and other potential contaminants. 

For more information on Lazarus Naturals and their product offerings, check out our review of the brand. 

Avatar for The CBD Insider
The CBD Insider Editorial Team

The mission of The CBD Insider is to provide consumers with a way to find high-quality, safe, and well-formulated CBD products. Our editorial team of passionate industry professionals achieves this mission by providing unbiased, trustworthy, and well-researched reporting about the CBD industry.